Correction: Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling

Ikuo Nakamura, Kais Zakharia, Bubu A. Banini, Dalia S. Mikhail, Tae Hyo Kim, Ju Dong Yang, Catherine D. Moser, Hassan M. Shaleh, Sarah R. Thornburgh, Ian Walters, Lewis R. Roberts

Research output: Contribution to journalComment/debate

1 Scopus citations
Original languageEnglish (US)
Article numbere0142355
JournalPloS one
Volume10
Issue number11
DOIs
StatePublished - Nov 3 2015

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Nakamura, I., Zakharia, K., Banini, B. A., Mikhail, D. S., Kim, T. H., Yang, J. D., Moser, C. D., Shaleh, H. M., Thornburgh, S. R., Walters, I., & Roberts, L. R. (2015). Correction: Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. PloS one, 10(11), [e0142355]. https://doi.org/10.1371/journal.pone.0142355